Article Text

Download PDFPDF

Paroxetine controlled release was effective and tolerable for treating menopausal hot flash symptoms in women
  1. Pamela Lotke, MD, MPH,
  2. Francisco Garcia, MD, MPH
  1. Univesity of Arizona
 Tucson, Arizona, USA

    Statistics from

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

 Q In women who are menopausal, is paroxetine controlled release (CR) effective and tolerable for treating vasomotor symptoms?

    Clinical impact ratings GP/FP/Primary care ★★★★★☆☆ Endocrine ★★★★★☆☆


    Embedded ImageDesign:

    randomised placebo controlled trial.

    Embedded ImageAllocation:


    Embedded ImageBlinding:

    blinded {patients, healthcare providers, data collectors, outcome assessors}.*

    Embedded ImageFollow up period:

    6 weeks.

    Embedded ImageSetting:

    17 sites (including urban, suburban, and rural clinics) in the US.

    Embedded ImagePatients:

    165 women ⩾18 years of age (mean age 54 y) who were menopausal (defined as amenorrhoea for ⩾12 consecutive mo, amenorrhoea for 6 mo and meeting the biochemical criteria for menopause, or history of bilateral oophorectomy ⩾6 wks before screening), experienced ⩾2–3 daily hot flashes or ⩾14 bothersome hot flashes/week, had discontinued hormone replacement therapy for ⩾6 weeks, and had discontinued psychotropic drugs for 2–12 weeks (specified for class of medication). Exclusion criteria included active cancer, active psychiatric disorder, concurrent major depression, intolerance to selective serotonin reuptake inhibitors (SSRIs), and substance dependence.

    Embedded ImageInterventions:

    after a 1 week placebo run in phase, women were allocated to receive paroxetine CR, 12.5 mg/day (n = 51) or 25 mg/day (n = 58), or placebo (n = 56) for 6 weeks.

    Embedded ImageOutcomes:

    self reported daily composite hot flash score, which was calculated by multiplying daily frequency and severity (minimum severity score 1, maximum severity score 4) ratings; hot flash frequency; and adverse events.

    Embedded ImagePatient follow up:



    After adjustment for age, disease history, and antioestrogen use, mean reductions from baseline in daily composite hot flash score were greater for patients who received paroxetine CR, 12.5 mg/day (8.52, p = 0.007) or 25 mg/day (7.43, p = 0.03) than for patients who received placebo (3.82). Similarly, mean reductions from baseline in daily hot flash frequency were greater for patients who received paroxetine CR, 12.5 mg/day (3.3, p = 0.01) or 25 mg/day (3.2, p = 0.01) than for patients who received placebo (1.8). Also, adjusted mean reductions from baseline in vasomotor symptom scores (measured by the Greene Climacteric Scale) were greater for patients who received paroxetine CR, 12.5 mg/day (1.75, p = 0.005) or 25 mg/day (1.55, p = 0.02) than for patients who received placebo (0.83). The groups did not differ for rates of adverse events, which were few and primarily mild or moderate in severity.


    In women who are menopausal, paroxetine controlled release was effective and tolerable for treating menopausal hot flash symptoms.


    In the wake of the Women’s Health Initiative1, many clinicians and patients have turned to nonhormonal therapies for menopausal symptomatic relief. In this study, Stearns et al examine whether the use of SSRIs is beneficial in symptomatic relief of hot flashes.

    In this study, paroxetine CR use is associated with decreases in hot flash frequency and composite scores in both of the study groups. It also confirms the safety of this agent, which has already been proven in the setting of depression. However, this study suffers from small sample size, high dropout rates, and a short follow up duration. Paroxetine CR was compared with a placebo control, but a hormonal therapy arm might have been more useful to determine comparability to the gold standard.

    This study enrolled only women with substantial hot flashes who had a mean age of 54 years (31% were aged >54 y). Any conclusions drawn from this study should therefore be limited to this relatively narrow perimenopausal demographic. Paroxetine CR may be an important alternative for the treatment of symptomatic women with true contraindications to menopausal hormone therapy. This includes women with breast cancer (who were, unfortunately, excluded from this study), coronary artery disease, or venous thromboembolic disease. SSRIs are an interesting and promising therapeutic alternative for relief of vasomotor symptoms; however, more studies with different subsets of women and larger numbers are needed to make any definite recommendation. In addition, short term hormone replacement therapy has not yet been dismissed as a treatment option.


    View Abstract


    • * See glossary.

    • Information provided by author.

    • For correspondence: Dr V Stearns, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD, USA.

    • Source of funding: Glaxo-SmithKline.

    Linked Articles

    • Glossary
      BMJ Publishing Group Ltd